This study is testing a drug called Sutetinib Maleate Capsule for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific uncommon changes (mutations) in the EGFR gene. Sutetinib Maleate Capsule is an investigational drug that works by blocking certain proteins (tyrosine kinase inhibitor) involved in cancer growth. Researchers want to see how well Sutetinib Maleate Capsule shrinks tumors (Objective Response Rate) over about 32 months. To join, you must be at least 18 years old, have NSCLC confirmed by a doctor, and your tumor must have an uncommon EGFR mutation. You also need to have at least one measurable tumor and a good general health score.

Study design

This is an interventional study with a planned enrollment of 66 participants. It is evaluating Sutetinib Maleate Capsule for non-small cell lung cancer.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for objective response rate from pre-dose up to approximately 32 months post-dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.